Release Details

TARRYTOWN, N.Y., Mar 09, 2009 (BUSINESS WIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Barclays Capital Global Healthcare Conference on Wednesday, March 11, 2009. The presentation, which is scheduled for 10:45 a.m. Eastern Time, will provide an overview of the Company, including its three Phase 3 clinical programs. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page under the Presentations heading. An archived version of the presentation will be available after the live webcast through April 10, 2009. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST^® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.

SOURCE: Regeneron Pharmaceuticals, Inc.

For Regeneron Pharmaceuticals, Inc.
Peter Dworkin, 914-345-7640
Investor Relations
peter.dworkin@regeneron.com
or
Laura Lindsay, 914-345-7800
Media Relations
laura.lindsay@regeneron.com
or
Kelly Hershkowitz, 212-845-5624
Media Relations
khershkowitz@biosector2.com